# name
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II

# metadata.dc.description.abstract[].value
Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.

# metadata.dc.relation.ispartof[].value
Journal of Clinical Medicine, 2019, vol. 8, num. 9, p. 1332

# metadata.dc.source[].value
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

# metadata.dc.title[].value
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II